Université De Reims Champagne-Ardenne

Jacques Henri Max Cohen

Annelise Gimenez

Xavier Dervillez

Daniel Baty

Béatrice Donvito

Wael Mahmoud

Marcelle Tonye Libyh

Nathalie Godin

Thierry Tabary

Brigitte Reveil

Aymric Kisserli

Fadi Haidar

Stéphane Oudin

Marcelle Tonye-Libyh

The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a heteromultimeric protein, is useful for redirecting an immune response that was pre-existing in a patient, toward an undesired target cell.

Protein constructs designed for targeting and lysis of cells

The invention concerns an internal standard used to quantitative analysis of the risk of humoral (i.e. vascular) transplant rejection. The internal standard consists of a stable composition of the C4d complement bound to a carrier consisting of erythrocytes or microparticles. The invention also concerns a method for analyzing in vitro the risk of humoral organ transplant rejection, which consists in determining the amount of component of C4d component fixed on the erythrocytes contained in a blood sample from a patient.

C4d/C4b standard for quantitative flow cytometry of humoral transplant rejection

A method for preparing recombinant dimeric proteins using a nucleic acid coding for the C-terminal fragment of the C4BP protein &#x3b2; chain including amino acid residues 193 to 252 or a functional variant of the fragment, wherein the fragment enables covalent bonding of the heterologous polypeptides to which it is fused. Dimeric proteins obtained by means of the method and cells for carrying out the method are also described.

Recombinant dimeric and heterodimeric proteins comprising amino acids 193 to 252 of the &#x3b2; chain of the human C4BP protein

Growing community of inventors

Reims, France

Jacques Henri Max Cohen